Show All

June 2011

Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, and Kolaja KL

Estimating the Risk of Drug-induced Proarrhythmia Using Human Induced Pluripotent Stem Cell-derived Cardiomyocytes

Toxicol Sci 123(1):281-9

Publication Date: June 20, 2011

Product Type: iCell Cardiomyocytes


Analysis of 28 compounds with known cardiac effects was performed using iCell Cardiomyocytes and the xCELLigence RTCA Cardio System. Compound-specific changes in cardiac beat rate and/or the amplitude of the impedance measurement were consistent with clinical findings. The results were confirmed using iCell Cardiomyocytes and a multielectrode array (MEA) platform.


iCell Cardiomyocytes responded to known cardiotoxic compounds in a manner consistent with clinical observations. Analysis was performed using two cell analysis platforms commonly used in the pharmaceutical industry.

Guo L, Qian JY, Abrams R, Tang HM, Weiser T, Sanders MJ, and Kolaja KL

The Electrophysiological Effects of Cardiac Glycosides in Human iPSC-derived Cardiomyocytes and in Guinea Pig Isolated Hearts

Cell Physiol Biochem 27(5):453-62

Publication Date: June 15, 2011

Product Type: iCell Cardiomyocytes


Pharmacological and toxicological effects of cardiac glycosides (ouabain, digoxin) and the L-type Ca2+ channel antagonist nifedipine were measured in iCell Cardiomyocytes using a multielectrode array (MEA) platform. The observed changes in field potential duration and Ca2+ wave amplitude correlated with the compounds’ effects on QT interval and contractility in guinea pig Langendorff hearts.


iCell Cardiomyocytes showed expected pharmacological and toxicological responses to compounds known to disrupt cardiac cell function through a variety of biochemical mechanisms